APPENDIX 2Additional Cost Comparators
Table 5Costs of Additional Comparators for the Treatment of Chronic Obstructive Pulmonary Disease
View in own window
Drug/Comparator | Strength | Dosage Form | Price ($) | Price/Dose ($) | Recommended Daily Use | Daily Drug Cost ($) | Average Annual Cost ($) |
---|
ICS |
---|
Budesonide (Pulmicort Turbuhaler) | 100 mcg 200 mcg 400 mcg | Inhalant pwd (200 doses) | 31.1600 63.7200 93.0000 | 0.16 0.32 0.46 | 200 mcg to 400 mcg twice daily | 0.64 to 0.93 | 233 to 339 |
Fluticasone propionate (Flovent Diskus, Flovent) | 50 mcg 100 mcg 250 mcg 500 mcg | Inhalant pwd (60 doses) | 15.1300a 23.9300a 41.2800 82.5400 | 0.25 0.40 0.69 1.38 | 100 mcg to 500 mcg twice daily | 0.80 to 2.75 | 291 to 1,004 |
50 mcg 125 mcg 250 mcg | Aerosol MDI (120 doses) | 23.9300 41.2800 82.5400 | 0.20 0.34 0.69 | 0.80 to 2.75 | 291 to 1,004 |
Ciclesonide (Alvesco) | 100 mcg 200 mcg | Solution aerosol (120 doses) | 45.2160 74.7600 | 0.38 0.62 | 100 mcg to 800 mcg once daily | 0.38 to 2.49 | 138 to 910 |
Short-acting muscarinic antagonist |
---|
Ipratropium Bromide (Atrovent) | 20 mcg | MDI (200 doses) | 18.9200 | 0.09 | 2 × 20 mcg 3 to 4 times daily | 0.57 to 0.76 | 207 to 276 |
SABA |
---|
Salbutamol (Airomir) | 100 mcg | Inhalant pwd (200 doses) | 5.0000 | 0.02 | 100 mcg to 200 mcg up to 4 times daily | 0.10 to 0.20 | 36 to 73 |
Salbutamol (Ventolin, generics) | 100 mcg | Inhalant pwd (200 doses) | 5.0000 | 0.02 | 100 mcg to 200 mcg up to 4 times daily | 0.10 to 0.20 | 36 to 73 |
Terbutaline (Bricanyl Turbohaler) | 0.5 mg | Inhalant pwd (200 doses) | 15.2800 | 0.08 | 0.5 mg up to 6 times daily | 0.08 to 0.46 | 28 to 167 |
Xanthine Bronchodilator |
---|
Theophylline (Uniphyl, generic) | 100 mg 200 mg 300 mg 400 mg 600 mg | SR Tab SR Tab SR Tab SR Tab SR Tab | 0.1300 0.1350 0.1750 0.5030 0.6090 | 0.13 0.14 0.18 0.50 0.61 | Once daily, generally 400 mg to 800 mg (varies with patient’s lean muscle mass) | 0.50 to 1.00 | 184 to 367 |
ICS = inhaled corticosteroid; MDI = metered dose inhaler; pwd = powder; SABA = short-acting beta-2 agonist.
- a
Saskatchewan Drug Plan (February 2015).
Source: Alberta Health Formulary (February 2015), unless otherwise stated.